Patents by Inventor Emily LU

Emily LU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240220658
    Abstract: A processing system may obtain baseline attributes associated with a plurality of representative files of a first type of network equipment, where the baseline attributes comprise a plurality of baseline checksums associated with the plurality of representative files, obtain snapshot attributes associated with a first plurality of files of a first device deployed in a communication network, where the first device is of the first type of network equipment, and where the first plurality of files is associated with at least a portion of the plurality of representative files, identify at least one file of the first plurality of files or at least one directory associated with the first plurality of files, for which a respective one of the snapshot attributes fails to match a respective one of the baseline attributes, and perform at least one remedial action in the communication network in response to the identifying.
    Type: Application
    Filed: December 30, 2022
    Publication date: July 4, 2024
    Inventors: Gregory Herrera, Robert Kong, Emily Lu, Brittany Vassallo, Meredith Gee
  • Patent number: 11752239
    Abstract: A combination bioactive silicate (e.g., bioactive glass) medicine carrier and shunt of one embodiment includes a shunt which is a tubular member made of bioactive silicate or glass being adapted to be bioresorbable and water soluble, or fiber bundle, the shunt including an insertion end at a first end. Gaps in the bioactive silicate or gaps in the glass adapted to be bioresorbable and water soluble are served as at least one storage for storing medicines.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: September 12, 2023
    Assignee: TAIWAN FIBER OPTICS, INC.
    Inventors: Luke Lu, Hsiao Sen Tseng, Michelle Lu, Emily Lu
  • Patent number: 11491051
    Abstract: A shunt for draining ocular fluid of one embodiment includes a tubular body formed of a mesh material including bioactive glass fiber and collagen, the tubular body including an implantation member and a conduit through the implantation member. The implantation member and the conduit are formed integrally. Other embodiments are also contemplated.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 8, 2022
    Assignee: TAIWAN FIBER OPTICS, INC.
    Inventors: Luke Lu, Hsiao Sen Tseng, Michelle Lu, Emily Lu
  • Patent number: 11007222
    Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 18, 2021
    Assignee: NEXIMMUNE, INC.
    Inventors: Mathias Oelke, Kristi Jones, Sojung Kim, Lauren Suarez, Ken Carter, Scott Carmer, Dan Bednarik, Vineetha Edavana, Emily Lu
  • Publication number: 20200215115
    Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
    Type: Application
    Filed: December 9, 2019
    Publication date: July 9, 2020
    Inventors: Mathias OELKE, Kristi JONES, Sojung KIM, Lauren SUAREZ, Ken CARTER, Scott CARMER, Dan BEDNARIK, Vineetha EDAVANA, Emily LU
  • Publication number: 20200188435
    Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
    Type: Application
    Filed: November 8, 2019
    Publication date: June 18, 2020
    Inventors: Mathias OELKE, Kristi JONES, Sojung KIM, Lauren SUAREZ, Ken CARTER, Scott CARMER, Dan BEDNARIK, Vineetha EDAVANA, Emily LU